Editas Medicine, Inc. Forecast, price target & analysts
Editas Medicine, Inc. Target price 2026 - Analyst rating & recommendation
Editas Medicine, Inc. Classifications & Recommendation
Editas Medicine, Inc. Price Target
| Target Price | $5.10 |
| Price | $2.58 |
| Potential |
97.67%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Editas Medicine, Inc. 2027 .
The average Editas Medicine, Inc. target price is $5.10.
This is
97.67%
register free of charge
$15.75
510.47%
register free of charge
$1.01
60.85%
register free of charge
|
|
| A rating was issued by 18 analysts: 12 Analysts recommend Editas Medicine, Inc. to buy, 4 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2027 of
97.67%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 40.52 | 26.44 |
| 25.41% | 34.75% | |
| EBITDA Margin | -232.13% | -394.93% |
| 67.83% | 70.13% | |
| Net Margin | -395.01% | -461.05% |
| 46.17% | 16.72% |
13 Analysts have issued a sales forecast Editas Medicine, Inc. 2026 . The average Editas Medicine, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2026. The average Editas Medicine, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Editas Medicine, Inc. Analysts have issued a net profit forecast 2026. The average Editas Medicine, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.80 | -0.79 |
| 37.50% | 56.11% | |
| P/E | negative | |
| EV/Sales | 10.08 |
13 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Editas Medicine, Inc....
Current Editas Medicine, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Ladenburg Thalmann |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Mar 10 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 09 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Ladenburg Thalmann:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Mar 10 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 09 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 05 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
